VERVE THERAPEUTICS IN

Verve Therapeutics Highlights Preclinical Data Supporting Nomination of VERVE-201 ANGPTL3 Product Candidate at the European Society of Cardiology 2022 Congress

22 Aug 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial Results

09 Aug 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

25 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

21 Jul 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Proposed Public Offering of Common Stock

20 Jul 2022 13:02:00 By Nasdaq GlobeNewswire

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

20 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Verve Therapeutics Doses First Human with an Investigational In Vivo Base Editing Medicine, VERVE-101, as a Potential Treatment for Heterozygous Familial Hypercholesterolemia

12 Jul 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. “Bo” Cumbo, to its Board of Directors

13 Jun 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

01 Jun 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results

10 May 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022

09 May 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in Upcoming May Investor Conferences

04 May 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia

26 Apr 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

04 Apr 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

24 Mar 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

23 Feb 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

10 Jan 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 03:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer

29 Nov 2021 05:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results

10 Nov 2021 03:30:00 By Nasdaq GlobeNewswire